Chk2 kinase - A busy messenger

Nature Reviews Molecular Cell Biology

Volumn 2, Issue 12, 2001, Pages 877-886

  Bartek, Jiri ^a   Falck, Jacob ^a   Lukas, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EUKARYOTA;

CDS1 KINASE; ENZYME INHIBITOR; PROTEIN KINASE;

ANIMAL; BIOLOGICAL MODEL; CELL CYCLE; CHEMISTRY; DRUG DESIGN; ENZYME ACTIVATION; EVOLUTION; GENETICS; HUMAN; MUTATION; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMAL; CELL CYCLE; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; EVOLUTION; GENES, TUMOR SUPPRESSOR; HUMAN; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 0035656415     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/35103059     Document Type: Review

References (97)

1. Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis. Science 274, 1664-1672 (1996).
2. Weinert, T. DNA damage and checkpoint pathways: molecular anatomy and interactions with repair. Cell 94, 555-558 (1998).
3. Walworth, N. C. Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr. Opin. Cell Biol. 12, 697-704 (2000).
4. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001).
5. Rotman, G. & Shiloh, Y. The ATM gene and protein: possible roles in genome surveillance, checkpoint controls and cellular defence against oxidative stress. Cancer Surv. 29, 285-304 (1997).
6. Hartwell, L. H. & Kastan, M. B. Cell cycle control and cancer. Science 266, 1821-1828 (1994).
7. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71, 543-546 (1992).
8. Weinert, T. Yeast checkpoint controls and relevance to cancer. Cancer Surv. 29, 109-132 (1997).
9. Dasika, G. K. et al. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18, 7883-7899 (1999).
10. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15, 2177-2196 (2001).
11. Zhou, B. B. & Elledge, S. J. The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439 (2000).
12. Lowndes, N. F. & Murguia, J. R. Sensing and responding to DNA damage. Curr. Opin. Genet. Dev. 10, 17-25 (2000).
13. Durocher, D. & Jackson, S. P. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opin. Cell Biol. 13, 225-231 (2001).
14. Khanna, K. K. & Jackson, S. P. DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genet. 27, 247-254 (2001).
15. Carr, A. M. Control of cell cycle arrest by the Mec1sc/Rad3sp DNA structure checkpoint pathway. Curr. Opin. Genet. Dev. 7, 93-98 (1997).
16. Murray, A. W. The genetics of cell cycle checkpoints. Curr. Opin. Genet. Dev. 5, 5-11 (1995).
17. Kastan, M. B. & Lim, D. S. The many substrates and functions of ATM. Nature Rev. Mol. Cell Biol. 1, 179-186 (2000).
18. Shiloh, Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 11, 71-77 (2001).
19. Shiloh, Y. & Rotman, G. Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J. Clin. Immunol. 16, 254-260 (1996).
20. Lavin, M. F. & Shiloh, Y. The genetic defect in ataxiatelangiectasia. Annu. Rev. Immunol. 15, 177-202 (1997).
21. Rhind, N. & Russell, P. Cnk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J. Cell Sci. 113, 3889-3896 (2000).
22. Matsuoka, S., Huang, M. & Elledge, S. J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-1897 (1998). The cloning of human and mouse Chk2. Together with references 23-26, this report shows that mammalian Chk2 is a functional homologue of S. cerevisiae Rad53 and S. pombe cds1, and a downstream effector of ATM.
23. Blasina, A. et al. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol. 9, 1-10 (1999).
24. Brown, A. L. et al. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc. Natl Acad. Sci. USA 96, 3745-3750 (1999).
25. Tominaga, K. et al. Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53. J. Biol. Chem. 274, 31463-31467 (1999).
26. Chaturvedi, P. et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogens 18, 4047-4054 (1999).
27. Hartwell, L. H. & Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. Science 246, 629-634 (1989).
28. Allen, J. B., Zhou, Z., Siede, W., Friedberg, E. C. & Elledge, S. J. The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev. 8, 2401-2415 (1994).
29. Murakami, H. & Okayama, H. A kinase from fission yeast responsible for blocking mitosis in S phase. Nature 374, 817-819 (1995).
30. Guo, Z. & Dunphy, W. G. Response of Xenopus Cds1 in cell-free extracts to DNA templates with double-stranded ends. Mol. Biol. Cell 11, 1535-1546 (2000).
31. Higashitani, A. et al. Caenorhabditis elegans Chk2-like gene is essential for meiosis but dispensable for DNA repair. FEBS Lett. 485, 35-39 (2000).
32. Oishi, I. et al. Critical role of Caenorhabditis elegans homologs of Cds1 (Chk2)-related kinases in meiotic recombination. Mol. Cell. Biol. 21, 1329-1335 (2001).
33. MacQueen, A. J. & Villeneuve, A. M. Nuclear reorganization and homologous chromosome pairing during meiotic prophase require C. elegans chk-2. Genes Dev. 15, 1674-1687 (2001).
34. Oishi, I. et al. A novel Drosophila nuclear protein serine/threonine kinase expressed in the germline during its establishment. Mech. Dev. 71, 49-63 (1998).
35. Rockmill, B. & Roeder, G. S. A meiosis-specific protein kinase homolog required for chromosome synapsis and recombination. Genes Dev. 5, 2392-2404 (1991).
36. Matsuoka, S. et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl Acad. Sci. USA 97, 10389-10394 (2000). This study and references 37 and 38 provide evidence for direct phosphorylation of Chk2 by the ATM and ATR kinases in vitro. ATM-dependent phosphorylation of threonine 68 was shown to be required for ionizing-radiation-induced Chk2 activation, also in vivo.
37. Melchionna, R., Chen, X. B., Blasina, A. & McGowan, C. H. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nature Cell Biol. 2, 762-765 (2000).
38. Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H. & Canman, C. E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60, 5934-5936 (2000).
39. Tanaka, K., Boddy, M. N., Chen, X. B., McGowan, C. H. & Russell, P. Threonine-11, phosphorylated by Rad3 and ATM in vitro, is required for activation of fission yeast checkpoint kinase Cds1. Mol. Cell. Biol. 21, 3398-3404 (2001).
40. Hofmann, K. & Bucher, P. The FHA domain: a putative nuclear signalling domain found in protein kinases and transcription factors. Trends Biochem. Sci. 20, 347-349 (1995).
41. Li, J., Lee, G. I., Van Doren, S. R. & Walker, J. C. The FHA domain mediates phosphoprotein interactions. J. Cell Sci. 113, 4143-4149 (2000).
42. Sun, Z., Hsiao, J., Fay, D. S. & Stern, D. F. Rad53 FHA domain associated with phosphorylated Rad9 in the DNA, damage checkpoint. Science 281, 272-274 (1998). The original report that identifies a role for the Rad53 FHA2 domain in phosphospecific interactions between Rad9 and Rad53.
43. Li, J., Smith, G. P. & Walker, J. C. Kinase interaction domain of kinase-associated protein phosphatase, a phosphoprotein-binding domain. Proc. Natl Acad. Sci. USA 96, 7821-7826 (1999).
44. Durocher, D., Henckel, J., Fersht, A. R. & Jackson, S. P. The FHA domain is a modular phosphopeptide recognition motif. Mol. Cell 4, 387-394 (1999).
45. Durocher, D. et al. The molecular basis of FHA domain: phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol. Cell 6, 1169-1182 (2000). A detailed in vitro binding analysis, which shows that FHA domains have high affinity for phosphothreonine residues. The FHA optimal recognition motif was identified as pTXXD (in which T is threonine, D is aspartic acid and X is any amino acid).
46. Lee, C. H. & Chung, J. H. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J. Biol. Chem. 276, 30537-30541 (2001). Evidence for an essential role of the Chk2 FHA domain and autophosphorylation of threonines 383 and 387 in the Chk2 activation loop for the full activation of the kinase.
47. Gilbert, C. S., Green, C. M. & Lowndes, N. F. Budding yeast Rad9 is an ATP-dependent Rad53 activating machine. Mol. Cell 8, 129-136 (2001). This study proposes an intriguing model of Rad53 activation whereby Mec1/Tel1-dependent phosphorylation of Rad9 converts the latter protein to a scaffold that brings two Rad53 molecules into close proximity.
48. Ward, I. M., Wu, X. & Chen, J. Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks. J. Biol. Chem. (in the press).
49. Bork, P. et al. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11, 68-76 (1997).
50. Kumagai, A. & Dunphy, W. G. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol. Cell 6, 839-849 (2000).
51. Alcasabas, A. A. et al. Mrc1 transduces signals of DNA replication stress to activate Rad53. Nature Cell Biol. 3, 958-965 (2001). This study and reference 52 indicates that in yeast, Mrc1 might serve as a replicative counterpart of Rad9 and crb2 in activation of the Rad53 and cds1 kinases, respectively.
52. Tanaka, K. & Russell, P. Mrc1 channels the DNA replication arrest signal to checkpoint kinase Cds1. Nature Cell Biol. 3, 966-972 (2001).
53. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y. & Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14, 289-300 (2000).
54. Chehab, N. H., Malikzay, A., Stavridi, E. S. & Halazonetis, T. D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl Acad. Sci. USA 96, 13777-13782 (1999). Phosphorylation of the serine 20 residue of p53 was shown to be required for its DNA-damage-dependent stabilization. This was soon followed by identification of Chk1 and Chk2 as the kinases that mediate this phosphorylation (references 53 and 55).
55. Chehab, N. H., Malikzay, A., Appel, M. & Halazonetis, T. D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14, 278-288 (2000).
56. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
57. Ryan, K. M., Phillips, A. C. & Vousden, K. H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332-337 (2001).
58. Hirao, A. et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287, 1824-1827 (2000). The first - and, so far, the only - report on Chk2-knockout mouse embryo fibroblasts, which indicates an involvement of Chk2 in DNA-damage-dependent stabilization of p53 and G2/M checkpoint arrest.
59. Lee, J. S., Collins, K. M., Brown, A. L., Lee, C. H. & Chung, J. H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404, 201-204 (2000). The association with, and phosphorylation of, BRCA1 by Chk2 was identified as an important event in BRCA1-dependent DNA-damage checkpoint function.
60. Scully, R. & Livingston, D. M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408, 429-432 (2000).
61. Xu, B., Kim, S. & Kastan, M. B. Involvement of BRCA1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol. Cell. Biol. 21, 3445-3450 (2001).
62. Wang, Y. et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14, 927-939 (2000).
63. Sanchez, Y. et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501 (1997).
64. Peng, C. Y. et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277, 1501-1505 (1997).
65. Zeng, Y. & Piwnica-Worms, H. DNA damage and replication checkpoints in fission yeast require nuclear exclusion of the Cdc25 phosphatase via 14-3-3 binding. Mol. Cell. Biol. 19, 7410-7419 (1999).
66. Graves, P. R., Lovly, C. M., Uy, G. L & Piwnica-Worms, H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 20, 1839-1851 (2001).
67. Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J. & Lukas, J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847 (2001). Identification of the Chk2-mediated degradation of the Cdc25A phosphatase as a rate-limiting step in the DNA damage intra-S-phase checkpoint in response to ionizing radiation.
68. Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425-1429 (2000). This report and reference 69 shows a rapid, checkpoint-dependent degradation of Cdc25A in response to ultraviolet radiation and stalled replication, respectively.
69. Molinari, M., Mercurio, C., Dominguez, J., Goubin, F. & Draetta, G. F. Human Cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep. 1, 71-79 (2000).
70. Petrini, J. H. The Mre11 complex and ATM: collaborating to navigate S phase. Curr. Opin. Cell Biol. 12, 293-296.
71. Kastan, M. B. Cell cycle. Checking two steps. Nature 410, 766-767 (2001).
72. Banin, S. et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677 (1998).
73. Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679 (1998).
74. Maya, R. et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15, 1067-1077 (2001).
75. Cortez, D., Wang, Y. Qin, J. & Elledge, S. J. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science 286, 1162-1166 (1999).
76. Tibbetts, R. S. et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev. 14, 2989-3002 (2000).
77. Li, S. et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 406, 210-215 (2000).
78. Barlow, C. et al. ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. Proc. Natl Acad. Sci. USA 97, 871-876 (2000).
79. Lukas, C. et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res. 61, 4990-4993 (2001). This study highlights the striking differences between human CHK2 and CHK1, and reports an unexpected correlation of CHK2 expression with tissue biology.
80. Bartkova, J. et al. Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours. Oncogens 20, 5897-5902 (2001).
81. Flaggs, G. et al. ATM-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes. Curr. Biol. 7, 977-986 (1997).
82. Kaneko, Y. et al. Cell cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogens 18, 3673-3681 (1999).
83. Bartek, J. & Lukas, J. Mammalian G1 - and S-phase checkpoints in response to DNA damage. Curr. Opin. Cell Biol. (in the press).
84. Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528-2531 (1999). The Identification of germline mutations in the CHK2 gene in Li-Fraumeni families with wild-type p53, which indicates a role for CHK2 as a tumour suppressor. Subsequently, identical and additional mutations were found In sporadic cancers of different origin (references 86-88).
85. Sodha, N. et al. Screening for hCHK2 mutations. Science 289, 359 (2000).
86. Haruki, N. et al. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res. 60, 4689-4692 (2000).
87. Hofman, W.-K. et al. Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk. Res. 25, 333-338 (2001).
88. Vahteristo, P. et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 61, 5718-5722 (2001).
89. Falck, J. et al. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20, 5503-5510 (2001). Evidence that the concomitant mutation of p53 and CHK2 might provide a selective advantage to tumour cells.
90. Wu, X., Webster, S. R. & Chen, J. Characterization of tumor-associated Chk2 mutations. J. Biol. Chem. 274, 2971-2974 (2001).
91. Matsuoka, S. et al. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res. 61, 5362-5355 (2001).
92. Yao, S. L. et al. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nature Med. 2, 1140-1143 (1996).
93. Suganuma, M., Kawabe, T., Hori, H., Funabiki, T. & Okamoto, T. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res. 59, 5887-5891 (1999).
94. Nghiem, P., Park, P. K., Kim, Y. Vaziri, C. & Schreiber, S. L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl Acad. Sci. USA 98, 9092-9097 (2001).
95. Yu, L. et al. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J. Biol. Chem. 273, 33455-33464 (1998).
96. Graves, P. R. et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600-5605 (2000).
97. Chen, M. S., Hurov, J., White, L. S., Woodford-Thomas, T. & Piwnica-Worms, H. Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol. Cell. Biol. 21, 3853-3861 (2001).